Osteoporosis is a progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history of fracture, advanced age, comorbidities, etc) that are present, the greater the risk of fracture.
Administration of the RANKL* inhibitor denosumab prior to chemotherapy initiation may prevent secondary reduction in bone mineral density (BMD) induced by chemotherapy, according to the ESPRESSO-02 study presented at ESMO Asia 2018.
Zoledronate significantly reduces the risk of both nonvertebral and vertebral fragility fractures over 6 years in older women with osteopenia — a substantial patient group at risk for fractures but in whom a knowledge gap remains for pharmacological treatment, reveals a large randomized trial.
Older individuals with osteoporosis who adopt a Mediterranean diet and take vitamin D supplements may experience significant improvements in femoral neck bone mineral density (BMD), according to the European-based NU-AGE* trial.
Treatment with denosumab in postmenopausal women with osteoporosis for 2 and/or 3, 5, and 10 years, compared with placebo, correlates with normal histology, low bone remodelling rate, increased matrix mineralization and lower mineralization heterogeneity, a recent study has shown. Such variables persist from years 5–10.
The RANKL* inhibitor denosumab is superior to the bisphosphonate risedronate in improving lumbar spine bone mineral density (BMD) at 1 year in patients newly starting or continuing steroid therapy, thus presenting a new treatment option for steroid-induced osteoporosis, a global study has shown.
Long-term use of inhaled corticosteroids (ICSs) at daily doses of ≥1,000 µg was associated with a modest but significant increase in nonvertebral fracture risk in patients with chronic obstructive pulmonary disease (COPD), according to a real-world study.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.